How adaptive optics will change retinal imaging
How adaptive optics will change retinal imagingAdaptive optics could allow clinicians to monitor the progression of retinal diseases cell-by-cell, according to Jacque Duncan, MD.
Systemic safety of anti-VEGF treatment for ROP mandates further study
Systemic safety of anti-VEGF treatment for ROP mandates further studyAccumulating evidence is cause for concern and underscoring the need for more research evaluating the safety of anti-VEGF injections for ROP, according to Robert L. Avery, MD.
Nystagmus diagnosis begins with thorough eye examA careful clinical workup, along with genetic testing, can help pinpoint what is behind congenital and infantile nystagmus.
ARVO 2017 showcases vision research advancesAdvances in presbyopia, dry eye and allergy, and age-related macular degeneration filled this year’s meeting of the Association for Research in Vision and Ophthalmology.
Inhibition of PlGF shows additional features compared to VEGF inhibition
Inhibition of PlGF shows additional features compared to VEGF inhibitionAnti-vascular endothelial growth factor (VEGF) remains the gold standard therapy for diabetic retinopathy, but “when treating diabetic macular edema (DME), “about half of the patients treated with VEGF inhibitors do not respond to therapy,” said Tine Van Bergen, PhD, a scientist with ThromboGenics, Leuven, Belgium.
Sirolimus shows promise for posterior segment non-infectious uveitisIntravitreal sirolimus 400 mcg (Ospiria, Santen) demonstrated positive results in pivotal trials investigating it as a treatment for non-infectious uveitis of the posterior segment. A New Drug Application is under FDA review.
Multifunctional OCT system approval simplifies imagingA newly approved system (3D OCT-1 Maestro, Topcon) combines a high-resolution, color, non-mydriatric retinal camera with the latest spectral-domain optical coherence tomography (OCT) technology, and stands out for its versatility as well as its quality and ease of use.
Real-world outcomes with aflibercept better in treatment-naïve patientsAfter 12 months of treatment with intravitreal aflibercept injections, both treatment-naïve and pre-treated patients demonstrated visual acuity gains. Visual acuity improvement was higher in treatment-naïve patients.
Ebola may leave retinal scarThe Ebola virus may leave a retinal scar specific to the disease, according to researchers. “The distribution of these retinal scars or lesions provides the first observational evidence that the virus enters the eye via the optic nerve to reach the retina in a similar way to West Nile virus,” said Dr Paul Steptoe of the Royal Liverpool Hospital, in a press release.
Selective techniques revolutionize treatment for retinoblastomaAdvancements in retinoblastoma have occurred in the areas of treatment, genetic testing, and diagnostic imaging.